<html>

<head>
    <link href="./static/vendor/bootstrap/css/bootstrap.css" rel="stylesheet">
    <link href="./static/css/outliers.css" rel="stylesheet">
    <meta charset="UTF-8">
</head>

<body>
    <div class="container">
        <h1>Static outliers for The Medical Centre</h1>
        <p>There is substantial variation in prescribing behaviours, across various different areas of medicine. Some variation can be explained by demographic changes, or local policies or guidelines, but much of the remaining variation is less easy to
            explain. At <a href="https://openprescribing.net/">OpenPrescribing</a> we are piloting a number of data-driven approaches to: identify unusual prescribing, collect feedback on this prescribing to inform development of new tools to support
            prescribers and organisations to audit and review prescribing.</p>
        <p>The below reports have been developed to use “z-scores” to automatically identify prescribing patterns at a chemical level which are furthest away from “typical prescribing” and can be classified as an “outlier”. It is important to remember that
            this information was generated automatically and it is therefore likely that some of the behaviour is warranted. This report seeks only to collect information about where this variation may be warranted and where it might not. Our full analytical
            method code is openly available on GitHub <a href="https://github.com/ebmdatalab/outliers/">here</a> but briefly we calculate the number of prescriptions for each chemical in the BNF coding system using the BNF subparagraph as a denominator.
            We used the time period from April 2021 to August 2021. We then calculate the mean and standard deviation for each numerator and denominator pair across all practices/CCGs/PCNs. From this we can calculate the “z-score”, which is a measure
            of how many standard deviations a given practice/CCG/PCN is from the population mean. We then rank your “z-scores” to find the top 5 results where prescribing is an outlier for prescribing higher than its peers and those where it is an outlier
            for prescribing lower than its peers.</p>
        <p>The DataLab is keen to hear your feedback on the results. You can do this by completing the following <a href="https://docs.google.com/forms/d/e/1FAIpQLSeH4ai_qyetAY4UAgZSWGnYQHkXNr9efFBmQvdrBi5uuXvgnQ/viewform?usp=pp_url&entry.2016356131=+">survey</a>            or emailing us at
            <a href="mailto:ebmdatalab@phc.ox.ac.uk?subject=OpenPrescribing%20outliers%20feedback">ebmdatalab@phc.ox.ac.uk</a>. Please DO NOT INCLUDE IDENTIFIABLE PATIENT information in your feedback. All feedback is helpful, you can send short or detailed
            feedback.
        </p>
        <h2>Prescribing where The Medical Centre is higher than most</h2>
        <table border="1" class="dataframe table thead-light table-bordered table-sm" id="table_high">
  <thead>
    
    
  <tr><th>BNF Chemical</th>
      <th><abbr title="number of prescribed items containing this chemical">Chemical Items</abbr></th>
      <th>BNF Subparagraph</th>
      <th><abbr title="count of all prescribed items from this subparagraph">Subparagraph Items</abbr></th>
      <th><abbr title="Ratio of chemical items to subparagraph items">Ratio</abbr></th>
      <th><abbr title="Population mean number of chemical items prescribed">Mean</abbr></th>
      <th><abbr title="Standard Deviation">std</abbr></th>
      <th><abbr title="Number of standard deviations prescribed item count is away from the mean">Z_Score</abbr></th>
      <th>Plots</th>
    </tr></thead>
  
<tbody><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=1003020Y0&amp;denomIds=10.3.2&amp;selectedTab=summary">Freeze sprays and gels</a><button type="button" data-toggle="collapse" data-target="#table_high_0_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>6</td>
      <td>Rubefacients, topical NSAIDS, capsaicin and poultice</td>
      <td>433</td>
      <td>0.01</td>
      <td>0.0</td>
      <td>0.0</td>
      <td>38.92</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_high_0_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=1003020Y0BDABAC&amp;denomIds=10.3.2&amp;selectedTab=summary" target="_blank">Deep Freeze Cold Gel 2% : 6</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0803042H0&amp;denomIds=8.3.4&amp;selectedTab=summary">Flutamide</a><button type="button" data-toggle="collapse" data-target="#table_high_1_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>2</td>
      <td>Prostate cancer and gonadorelin analogues</td>
      <td>39</td>
      <td>0.05</td>
      <td>0.0</td>
      <td>0.0</td>
      <td>14.39</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_high_1_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0803042H0AAAAAA&amp;denomIds=8.3.4&amp;selectedTab=summary" target="_blank">Flutamide 250mg tablets : 2</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=1104020N0&amp;denomIds=11.4.2&amp;selectedTab=summary">Nedocromil sodium</a><button type="button" data-toggle="collapse" data-target="#table_high_2_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>1</td>
      <td>Other anti-inflammatory preparations</td>
      <td>73</td>
      <td>0.01</td>
      <td>0.0</td>
      <td>0.0</td>
      <td>9.14</td>
      <td><img class="zoom" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAPwAAABICAYAAADS8JgEAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADh0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uMy4xLjMsIGh0dHA6Ly9tYXRwbG90bGliLm9yZy+AADFEAAANK0lEQVR4nO2dabQcRRWAv44YjIgiUXEDShGjQgKux4BLNApKqajIyYmgyBYEIhKIUCgqgsEibAKGGIIBMaBHRHApVEBJcAE1sojiQtRyC4uCQAQCmLQ/bj2dTOa96X7TM/0yc79z3pnkdVfdW2/6Vt26das6y/McRVEGg3F1K6AoSu9Qg1eUAUINXlEGCDV4RRkg1OAVZYBQg1eUAUINXlEGCDV4RRkg1OAVZYBQg1eUAUINvpdkmeYxK7WySd0KNGNceDxwDrAoentT3fooSj8xpgw+GfuXgR2BewA1eEWpkDHj0jcY+93AnsD0ejVSlP5jTBh8MvavAHcBhwO/B7YyLmxRq2KK0meMCYMHjgfuBWZHb/PobQ4sA6bVqZSi9BtjxeB3ARYkQx/iGtStV5RKGSsG/2LgN02/+z7wphp0UZS+pXaDNy5sBdwfvX2k8ffR2zuBtcaF59SjmaL0H7UbPDAZ+OUw19StV5QK2RgMXt16RamIsWDwU4Bbh7l2HfB640LWQ30UpW8ZKwbfcoSP3j4A/A14UU81UpQ+pVaDNy5sAjwb+OsIt6lbrygVUfcI/wJgZdP6ezO6PKcoFVG3wY8UsBviBuAVyRtQFKUD6jb4YefvQ0RvHwV+BuzbE40UpY8Z8wafOBw43rjwyi7royh9Td0GvyPwq3Y3RW9XATOBLxsXntV1rRSlT8nqenusceHJwE3R2+1KlNkXmA1Mi96uGaHe1wJXtgkG9p4sy8nzwjkFxoWnA8uB3aK3f+ueYsqgUOcIvyPDJ9y0JHq7FEnGOc+4sFVjQo5xYXvjwlmIx3AmsPdolDIuTDEuzBlN2S5wInA/8Om6FVH6gzoNfjIlDT5xHLAauBq4w7jwG+PCDcA3kYMzXgLsAZxiXHhqmYrTSsAS4Djjwtaj0K0yjAuTkfMApgMvNy68tE59lP6gzqWuKcghF6WI3q5FgnikEX4L4JnA76K369JtK40LnwdOBQ4qUf2HEA/hS8Bc4MNl9auC1K4zgWOjtw8ZF44FTjcuTB9z0xRlo6JOg58MnN1JBenh/1f6aeYM4GfGhWnR22Xt6jIubAMcAbwSeAi4zbhwcvT2rk50HCVvS5/fSp/fAeYAb0c8GUUZFbW49GkE2x5Y2S0Z0dvHgIOBhcaFCQX0WQB8Mnr7z+jtQ8AixMgqxbiwm3HhKSNcHw/MB44aGs3T51zAp/P/qtJlvHHhSVXVp4x96prDbw38PbnnXSN6uwIZHY9vc+tewATElR9iATCzbBygAFeQpiTDcDiwPHq7Xn5C9PYW4HrgkAp1WQycX2F9A4FxYZxx4VzjwpZ161KWugy+SEptVXwC2DsFwTYgnYx7CnBo4/w47dT7IjKvr5LTgYNajdRp5D8y6dyKjwNzjQubdqqEceEtyNFirzIuPLPT+jZmjAubGBfOMS68pGCR1wIzgAs2tq3bdRn8q4GbeyEoevtvJPi22LjwuMZr6ctaBCyM3t7eovhZwIHGhc071cO4MCX980RkpH5Xi9uOBL4Uvb27VR0pAek64B0d6rI58nafA4EL0+dAYlwYB1wA7IqsABVhf8QTy6l+QOgqPTf4tPS1D3Bpr2RGb78D/BE4rOnS/kiU/4xhyt0DfBX4SAVqzE91PoYEK49ovJimDgcMp0sD5yOxibYYF55gXNi5xaV5wCXR21tTfQc0d4aDQEPsZhwwFdjVuPDcNmU2R5ZKr0C+rw8ZF17ebV2roo4Rfg/gxujtHT2WeyRw9ND6unFhEjK3369hOa8V84DdjAtFe/8NMC68Gdhs6P/R258Cj296UOYAF0Zv721T3Q+BrY0Lzysg+ijgB8aFy4wLL0i67AK8ATg56bIKuBGwRdvTDyRjPxV4FvCBdIjqubQfsd8DfCt6uyZ9Vx8AlqYMz6KyJ6YpVc+pw+A/CCzstdDkJp8AnJvmwJcgL764s025+5D9+NONC77snC2NnPORKHsjZ5MerhT82Q9Ze2/XjhxJDtq/jdwtkADfJOBy4LvGhTOB84BZTacEL2RD72dEjAuZcWG2ccEZF6aPtPLQDYwLEzrcV3E0kgsyI3ldIEHMmW2mcPsjUwAAorc/Bi6i3DN9MnCpccGU0rgCemrwaVR6PnBtL+U28EUkGv8D4IfR2yuLFEpxgLchR20tLOn+7gv8Po3qjVwKTDMuPAN5+L6QOpciXAS8r80ZAXOAi6K3/0gpyZOR9/Ytjd5e33TvtcA2Q15AO1Kn55G/yX+AWcCNKevx0KJLh8aFHUYT9DIuPAH4NrDcuPDEUZTfDung3tPY8UVv7we+xjAxjfT32RJY0XTpFOA5xoV3F5A9GQn6HYUEcHtKr0f4g4HFbVzorpFGx0OAVcCxJcuuQdy5zZB5X1tSD35CK1lpn/8FSKBoXyRAWFSXuxA3fPdh5E5EXM3TG8o8HL39TPTWt6gvBz5PgSW/ZKAnAzsB74zenha9nZE2Qe2OJC7dbFzYcyRjNi4chmRaLi+z7bnhPYQrEOMstc8g6XQ28LG0EtPMWcDsYTrT/ZBp13rZjul5Phg4baRl3CT7DMABXwCebVzo6WlOPTP4lFCyDxIVro3o7R+it3s3v/iiYNn/IC7dJOPCiCm7qb1fAeZGb+Mwty1Cor2L0uhShsUMnzY8F+lYi3oMIF7DjJGSlNIDOw94GWLs6+1YjN7+JXp7APBeZARdlkbT5nreirR7EmKw5xsXLmnn4qaI+hLgDsRoTkTiK7sUbqVkKz4R+W42IHr7Z+DnSG5Gs+z3AkuHKXc70mmeNoLsPYDHITGAdciU7rNVJlO1o5cj/LuQhJJ7eiizcpLRzwCcceFVI9z6GeDn0dvLRqjrTmSf/2hSjK8GpjTPY9MUYSYlPIaky33A94BPtBrdkut8FvAKWhh7U123RG93Bz4LXGNc+J/xpOXJBcCe0dt7o7dXIR3INUiA8aBWnkH63eeQZ/bw9NLRNUint7hdNmVDG04jvbR0hFtPR/IdGvV4I3Bbm5jPGcBOrUbtZNTNGZQrkCXani3t9dLgP4j0gBs9KQC4D3CxkT3r62Fc2BN4PRsG6lrVdVmKEZTVYS2SGbhf0yUHnBu9XV22TuAYJGr9k4a8AYwL05EpxBrEUB8uqOPlyIrAMcaFs40L2wKXAe+P3q5suG9t9HYJsjS2FxLQ2jLJ3sS4MANx4bdAIurrGsregGRTnlBAJQd8I3r76zZ6r0DedbjKuLDMyLbrj9PGO02DwYFIYHizpsuHADdEb5vzTz4KHNGr5KeuH4CResldkCWPnftpt5dxYRYy2g/NpTcHtkWi4m+K3v5hvQIlD8AoIH8b4MdIAsg/088LgR2itw92UO9uyGj6NaQDmAwcHL29aZT1jUeCfIcBB0ZvLx7h3nHIiDcbCbK+H/gFcGr09sZhykxI9xwHfLfVdM248CIgIM9goc4weTqTkHjF84H5KfbSrtw8ZK/I9UjMZzPE65raajk6xTNmIZH+SwsszY6aygw+jQLjG362Bl6DBHFWASekBJi+ocHN3Bt4BNmnvxqYF73dcFdbxQbfoMd4YCLwNOC+6O1I5/wXrfNJyOjzD+CcNHp1Wudzi57cY1zYCfm7Lone/rHA/S8DPoVMD1YCP0K+k50Rg10HzInefnuU6hcmrSIMba3+N/Ag8KvkObS6PwNeigRv90I6r2XAA6n8amAtYlebps8ceBR4pJRd5XleyQ8wq6q6xoosbdPGIasf29QtWVXO4WdVWNdYkaVt2jhk9WObuiKr7lNrFUXpIWrwijJAVGnw51VY11iRpW3aOGT1Y5u6Iqu2c+kVRek96tIrygBR6tTaLMtehyTR3J3n+ZIsy94NbIese/4ayT77F7I2PbSp4WN5npc+u66ErAuRDL4r8zy/qGI5fwJ8nudvybJsIpI593Ce5yeWlVNS1s5IhPaqPM+vqFjOfenaauDiLrepUdZ1nbSpgKyVSALUY0i++6jbVULO8m62Kc/zy7Msm4kkcy3upE1DlB3hp+Z57oGhdNLt8zw/FcnusoiRb4okOlyN5EfvNErdispahxh+6W2S7eTkeX4z/z87fxpyOsyqLMtGe3hhUVmPIkbSjTZdi2S9TaT7bWqU1Wmb2sm6FXmeJ9B5u4rK6WqbsizbAdkoBNV8V6UNvnnC380AQCFZeZ4/kOf5ocCmWZaN5uy5sdim2/I8PxZJ5+yGnGOQEaMKCsmqoE1tZeV5Ph/JTuuUQnJ60KapSKbgrh3Uvx6lgnbJ/ZgK3ItsptgWcT9uRzYbzERG2wXASanY8R249EVkfR1x758BHJ2XjEK2kXMLspNtKeKtHI24VCe1rq0yWbchh0uMz/P8UxXL2QrZ8XYVchBIN9vUKOu3nbSpgKwH07WHkHMGRt2uEnK+1802DU0TsixzSAfd0XcFGqVXlIFCo/SKMkCowSvKAKEGrygDhBq8ogwQavCKMkCowSvKAKEGrygDhBq8ogwQavCKMkCowSvKAKEGrygDxH8Bv59WVleeUasAAAAASUVORK5CYII="></td>
    </tr>
    <tr id="table_high_2_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=1104020N0AAAAAA&amp;denomIds=11.4.2&amp;selectedTab=summary" target="_blank">Nedocromil 2% eye drops : 1</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=1003020F0&amp;denomIds=10.3.2&amp;selectedTab=summary">Benzydamine hydrochloride</a><button type="button" data-toggle="collapse" data-target="#table_high_3_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>4</td>
      <td>Rubefacients, topical NSAIDS, capsaicin and poultice</td>
      <td>433</td>
      <td>0.01</td>
      <td>0.0</td>
      <td>0.0</td>
      <td>8.29</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_high_3_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=1003020F0AAAAAA&amp;denomIds=10.3.2&amp;selectedTab=summary" target="_blank">Benzydamine 3% cream : 4</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0206020M0&amp;denomIds=2.6.2&amp;selectedTab=summary">Nimodipine</a><button type="button" data-toggle="collapse" data-target="#table_high_4_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>3</td>
      <td>Calcium-channel blockers</td>
      <td>3844</td>
      <td>0.00</td>
      <td>0.0</td>
      <td>0.0</td>
      <td>8.18</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
  <tr id="table_high_4_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0206020M0AAABAB&amp;denomIds=2.6.2&amp;selectedTab=summary" target="_blank">Nimodipine 30mg tablets : 3</a></div></td></tr></tbody></table>

        <h2>Prescribing where The Medical Centre is lower than most</h2>
        <table border="1" class="dataframe table thead-light table-bordered table-sm" id="table_low">
  <thead>
    
    
  <tr><th>BNF Chemical</th>
      <th><abbr title="number of prescribed items containing this chemical">Chemical Items</abbr></th>
      <th>BNF Subparagraph</th>
      <th><abbr title="count of all prescribed items from this subparagraph">Subparagraph Items</abbr></th>
      <th><abbr title="Ratio of chemical items to subparagraph items">Ratio</abbr></th>
      <th><abbr title="Population mean number of chemical items prescribed">Mean</abbr></th>
      <th><abbr title="Standard Deviation">std</abbr></th>
      <th><abbr title="Number of standard deviations prescribed item count is away from the mean">Z_Score</abbr></th>
      <th>Plots</th>
    </tr></thead>
  
<tbody><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=091101000&amp;denomIds=9.11.1&amp;selectedTab=summary">Other amino acidandnutritional agent preparations</a><button type="button" data-toggle="collapse" data-target="#table_low_0_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>0</td>
      <td>Amino acids and nutritional agents</td>
      <td>1</td>
      <td>0.00</td>
      <td>0.95</td>
      <td>0.20</td>
      <td>-4.82</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_low_0_items" class="collapse"><td colspan="9" class="hiddenRow"><div></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0501021L0&amp;denomIds=5.1.2&amp;selectedTab=summary">Cefalexin</a><button type="button" data-toggle="collapse" data-target="#table_low_1_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>24</td>
      <td>Cephalosporins</td>
      <td>34</td>
      <td>0.71</td>
      <td>0.96</td>
      <td>0.10</td>
      <td>-2.48</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_low_1_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0501021L0AAACAC&amp;denomIds=5.1.2&amp;selectedTab=summary" target="_blank">Cefalexin 125mg/5ml oral suspension : 2</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0501021L0AAABAB&amp;denomIds=5.1.2&amp;selectedTab=summary" target="_blank">Cefalexin 500mg capsules : 9</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0501021L0AAAAAA&amp;denomIds=5.1.2&amp;selectedTab=summary" target="_blank">Cefalexin 250mg capsules : 4</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0501021L0AAAGAG&amp;denomIds=5.1.2&amp;selectedTab=summary" target="_blank">Cefalexin 250mg tablets : 4</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0501021L0AAAHAH&amp;denomIds=5.1.2&amp;selectedTab=summary" target="_blank">Cefalexin 500mg tablets : 5</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0401020K0&amp;denomIds=4.1.2&amp;selectedTab=summary">Diazepam</a><button type="button" data-toggle="collapse" data-target="#table_low_2_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>80</td>
      <td>Anxiolytics</td>
      <td>188</td>
      <td>0.43</td>
      <td>0.75</td>
      <td>0.14</td>
      <td>-2.42</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_low_2_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0401020K0AAAHAH&amp;denomIds=4.1.2&amp;selectedTab=summary" target="_blank">Diazepam 2mg tablets : 68</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0401020K0AAAWAW&amp;denomIds=4.1.2&amp;selectedTab=summary" target="_blank">Diazepam 2mg/5ml oral solution sugar free : 2</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0401020K0AAAIAI&amp;denomIds=4.1.2&amp;selectedTab=summary" target="_blank">Diazepam 5mg tablets : 10</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0&amp;denomIds=1.1.2&amp;selectedTab=summary">Alginic acid compound preparations</a><button type="button" data-toggle="collapse" data-target="#table_low_3_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>940</td>
      <td>Compound Alginates and proprietary indigestion preparations</td>
      <td>970</td>
      <td>0.97</td>
      <td>1.00</td>
      <td>0.01</td>
      <td>-2.03</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_low_3_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0AAALAL&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Sodium algin 500mg/Potassium bicarb 100mg/5ml susp SF : 152</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BEAIAL&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Gaviscon Advance oral suspension aniseed (Reckitt Benckiser) : 184</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BEBEAL&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Gaviscon Advance oral susp peppermint (Reckitt Benckiser) : 245</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BIAAAH&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Peptac liquid aniseed : 83</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BIABAH&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Peptac liquid peppermint : 148</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BEAFAH&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Gaviscon Peppermint Liquid Relief : 1</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BEADAJ&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Gaviscon Infant oral powder sachets : 23</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BEARA0&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Gaviscon Double Action chewable tablets mint : 13</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BEAQAP&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Gaviscon Advance Mint chewable tablets (Reckitt Benckiser) : 27</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BEACAH&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Gaviscon Original Aniseed Relief : 8</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0AAAPAP&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Sodium algin 500mg/Potassium bicarb 100mg chew tab SF : 26</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0BEAUAR&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Gaviscon Peppermint chewable tablets : 6</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0101021B0AAAHAH&amp;denomIds=1.1.2&amp;selectedTab=summary" target="_blank">Alginate raft-forming oral suspension sugar free : 24</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0&amp;denomIds=3.1.1&amp;selectedTab=summary">Salbutamol</a><button type="button" data-toggle="collapse" data-target="#table_low_4_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>1802</td>
      <td>Selective beta(2)-agonists</td>
      <td>2211</td>
      <td>0.82</td>
      <td>0.91</td>
      <td>0.05</td>
      <td>-1.99</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
  <tr id="table_low_4_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0AAAPAP&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Salbutamol 100micrograms/dose inhaler CFC free : 1156</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0AAAXAX&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose vials : 69</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0AABUBU&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Salbutamol 100micrograms/dose breath actuated inh CFC free : 86</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0BEAIAP&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Ventolin 100micrograms/dose Evohaler : 78</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0BWAABZ&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Easyhaler Salbutamol sulfate 100micrograms/dose dry pdr inh : 329</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0BMABBU&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Airomir 100micrograms/dose Autohaler : 1</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0AABDBD&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Salbutamol 5mg/2.5ml nebuliser liquid unit dose vials : 22</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0AABGBG&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Salbutamol 2mg/5ml oral solution sugar free : 21</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0BEAHAQ&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Ventolin 200micrograms/dose Accuhaler : 11</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0BIAGBU&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Salamol 100micrograms/dose Easi-Breathe inhaler : 24</a><br><a href="https://openprescribing.net/analyse/#org=practice&amp;orgIds=B86062&amp;numIds=0301011R0BWABAQ&amp;denomIds=3.1.1&amp;selectedTab=summary" target="_blank">Easyhaler Salbutamol sulfate 200micrograms/dose dry pdr inh : 5</a></div></td></tr></tbody></table>

    </div>
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.3/jquery.min.js"></script>
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.5/js/bootstrap.min.js"></script>
</body>

</html>